• M R Cantudo-Cuenca, E Calvo-Cidoncha, M A Robustillo-Cortés, M C Saborido-Cansino, G Gómez-Estrella, and A Sánchez-Pedrosa.
• Unidad de Gestión Clínica de Farmacia, Área de Gestión Sanitaria Sur de Sevilla, Sevilla, España. Electronic address: rosa_cantudo@hotmail.com.
• Aten Primaria. 2016 Jan 1; 48 (1): 495349-53.

ObjectiveTo analyse the impact of a strategy on the suitability of strontium ranelate, and its level of acceptance, after issuing recommendations based on drug surveillance alerts issued by the Spanish Medicines and Medical Devices Agency.DesignA prospective interventional study conducted from April 2012 to November 2014.SettingSouth Seville Health Management Area.ParticipantsPatients currently prescribed with strontium ranelate.InterventionsThe study consisted of four phases linked to the issue of drug surveillance alerts on strontium ranelate by the Spanish Medicines and Medical Devices Agency, listed by patients and suitability recommendations.Main MeasurementsSuitability of strontium ranelate treatment and the level of acceptance by physicians.ResultsThere was a reduction of 87.9% in prescriptions from the beginning of the study, with 182 patients included, until the review of the suitability of the drug began. The prescribing of strontium ranelate was unsuitable in 16 out of the 22 patients remaining; 11 of which were due not meeting the treatment criteria, 3 for not having had previous treatments with other drugs for the prevention of fractures, and 2 due to contraindications. The level of acceptance of the recommendations was 87.5%, leading to the stopping of strontium ranelate in 10 patients, and the changing to alendronate or alendronate/cholecalciferol in another four patients.ConclusionsThe number of patients prescribed strontium ranelate has decreased considerably. The interventions directed at reviewing the suitability of this treatment, based on the drug surveillance alerts, have been effective.Copyright © 2014 Elsevier España, S.L.U. All rights reserved.

21 keywords...

hide…